Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Drug may ease emotional pain after pregnancy loss procedure

NCT ID NCT07537894

Symptom relief Sponsor: Stanford University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests whether giving a medicine called dexmedetomidine during a second-trimester dilation and evacuation (D&E) can lower the chances of severe grief and post-traumatic stress after the procedure. About 100 people having a D&E in the operating room will be randomly assigned to receive the drug or a placebo. The goal is to see if calming the body's stress response during the procedure can improve emotional recovery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * English- or Spanish-fluency * 16-26 weeks gestation * D\&E in the operating room Exclusion Criteria: * Unscheduled or emergent procedure * Contraindication to dexmedetomidine per package insert * Judgement of clinical anesthesiologist providing care

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Abortion are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Fetal Death post-traumatic stress disorder pregnancy disorder with abortive outcome pregnancy loss, recurrent, susceptibility to, 1 Prolonged Grief Disorder Stillbirth

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Abortion Grief (traumatic grief and existential grief) PTSD (childbirth-related) Stillbirth

Contacts and locations

Locations

  • Stanford Health Care

    Palo Alto, California, 94062, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.